PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma

por Sharma, Gaurav, Ojha, Rani, Noguera-Ortega, Estela, Rebecca, Vito W., Attanasio, John, Liu, Shujing, Piao, Shengfu, Lee, Jennifer J., Nicastri, Michael C., Harper, Sandra L., Ronghe, Amruta, Jain, Vaibhav, Winkler, Jeffrey D., Speicher, David W., Mastio, Jerome, Gimotty, Phyllis A., Xu, Xiaowei, Wherry, E. John, Gabrilovich, Dmitry I., Amaravadi, Ravi K.
Publicado 2020

PPT1 inhibition enhances the antitumor activity of anti–PD-1 antibody in melanoma

por Sharma, Gaurav, Ojha, Rani, Noguera-Ortega, Estela, Rebecca, Vito W., Attanasio, John, Liu, Shujing, Piao, Shengfu, Lee, Jennifer J., Nicastri, Michael C., Harper, Sandra L., Ronghe, Amruta, Jain, Vaibhav, Winkler, Jeffrey D., Speicher, David W., Mastio, Jerome, Gimotty, Phyllis A., Xu, Xiaowei, Wherry, E. John, Gabrilovich, Dmitry I., Amaravadi, Ravi K.
Publicado 2022

A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

por Rosenfeld, Myrna R, Ye, Xiaobu, Supko, Jeffrey G, Desideri, Serena, Grossman, Stuart A, Brem, Steven, Mikkelson, Tom, Wang, Daniel, Chang, Yunyoung C, Hu, Janice, McAfee, Quentin, Fisher, Joy, Troxel, Andrea B, Piao, Shengfu, Heitjan, Daniel F, Tan, Kay-See, Pontiggia, Laura, O’Dwyer, Peter J, Davis, Lisa E, Amaravadi, Ravi K
Publicado 2014

Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma

por Rangwala, Reshma, Leone, Robert, Chang, Yunyoung C, Fecher, Leslie A, Schuchter, Lynn M, Kramer, Amy, Tan, Kay-See, Heitjan, Daniel F, Rodgers, Glenda, Gallagher, Maryann, Piao, Shengfu, Troxel, Andrea B, Evans, Tracey L, DeMichele, Angela M, Nathanson, Katherine L, O’Dwyer, Peter J, Kaiser, Jonathon, Pontiggia, Laura, Davis, Lisa E, Amaravadi, Ravi K
Publicado 2014